Introduction
Compound A is a potent and highly selective non-steroidal mineralocorticoid receptor (MR) antagonist being developed for the treatment of diabetic nephropathy and other potential indications. Richly sampled PK data collected in phase 1 studies exhibited complex PK profiles for Compound A (secondary and tertiary peaks as well as prolonged absorption profiles following initial peak concentrations in conjunction with dose-dependent reductions in exposure with increasing doses) and its major metabolite (Metabolite B; slow formation and elimination).
Population Approach Group in Europe (PAGE), June 6-9 2017, Budapest, Hungary
By Tadakatsu Nakamura, Tomoko Kubota, David Jaworowicz, Kuan-Ju Lin, Atsuhiro Kawaguchi